U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441694) titled 'Study of INCA036978 in Participants With Myeloproliferative Neoplasms' on Feb. 13.
Brief Summary: This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Study Start Date: Feb. 26
Study Type: INTERVENTIONAL
Condition:
Myeloproliferative Neoplasms
Intervention:
DRUG: INCA036978
INCA036978 will be administered at protocol defined dose.
DRUG: Standard disease-directed therapy
A standard disease-directed the...